Clinical trialNCT00683449TerminatedPhase 2Interventional

Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma

SponsorMediciNovaEnrollment29AsthmaStatus Asthmaticus

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The objective of this clinical study is to examine the safety and effectiveness of intravenous MN-221 compared to placebo when administered as an adjunct to standard therapy in subjects experiencing an acute exacerbation of asthma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Michael Kalafer, MD
MediciNova
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Maricopa Medical Center; Dept. of Emergency Medicine
Phoenix, Arizona, United States
Lac + Usc Medical Center
Los Angeles, California, United States
Olive View - Ucla Medical Center
Sylmar, California, United States
Henry Ford Health System
Detroit, Michigan, United States
Washington University School of Medicine; Div. of Emergency Medicine
St Louis, Missouri, United States
New York Methodist Hospital
Brooklyn, New York, United States
Long Island Jewish Medical Center
New Hyde Park, New York, United States
Metrohealth Medical Center
Cleveland, Ohio, United States
Albert Einstein Medical Center
Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dose Group 1Dose Group 2Dose Group 3MN-221 placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Jun 2008
Primary completion: 31 Mar 2009
Completion: 31 Mar 2009
Last update posted: 7 Oct 2011
Registered enrollment: 29
Registry id: NCT00683449

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.